Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4Expanded_access 1

Sponsor

Cancer Type

Breast 4CNS 1

Conditions

Neoplasms 5Triple Negative Breast Neoplasms 4Breast Neoplasms 4Recurrence 2Ovarian Neoplasms 2Hypersensitivity 2Brain Neoplasms 2Squamous Cell Lung Cancer 1Solid Tumors 1Neoplasm Metastasis 1Glioblastoma 1Fanconi Anemia, Complementation Group D1 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Female 1Advanced Solid Tumors 1Advance Solid Tumors 1

Interventions

pembrolizumab 160Carboplatin 143Paclitaxel 125Cyclophosphamide 93130-nm albumin-bound paclitaxel 66Capecitabine 63Gemcitabine 54Doxorubicin 49Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 40Cisplatin 37Nivolumab 34sacituzumab govitecan 32olaparib 32Epirubicin 32Docetaxel 28eribulin 27Specimen Handling 26Bevacizumab 26durvalumab 25camrelizumab 23Drug Therapy 22Biopsy 22Magnetic Resonance Spectroscopy 21toripalimab 18Radiotherapy 17spartalizumab 16Everolimus 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Triple Negative Breast Neoplasms × iniparib × Clear all
NCT00813956 2016-03-17

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Sanofi

Phase 2 Completed
80 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01173497 2016-03-17

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Sanofi

Phase 2 Completed
44 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00938652 2013-09-19

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Sanofi

Phase 3 Completed
519 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00540358 2012-12-28

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Sanofi

Phase 2 Completed
123 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡